Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Firm Seeks To Prove New Drugs Can Be Developed Cheaply

This article was originally published in PharmAsia News

Executive Summary

An investment company in India has poured more than $61 million into five companies as part of an effort to prove drug development can be done more cheaply than is the practice today. Nadathur Holdings and Investments says it seeks to disprove the assumption new-drug development requires as much as $1 billion. Nadathur has created Lifespring Ventures as a subsidiary, now owner itself of five start-up firms in the drug-discovery process. The firms operate as stand-alone companies trying to find treatments focusing on metabolic syndrome connected to heart, stroke and diabetes conditions. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts